Strategic Focus Targeting solid tumors with a precision oncology platform and a lead ADC TGW101 against TAG72, presenting a clear near-term opportunity to engage oncology teams pursuing TAG72-expressing cancers and to position Tagworks as a differentiated partner for ADCs and radiopharmaceuticals.

Clinical Progression Active development with Phase 0/1 imaging study and a newly appointed CMO following IND clearance signals imminent clinical milestones, enabling timely outreach to potential collaborators, contract research organizations, and academic centers for investigator-initiated trials.

Strategic Partnerships Recent collaborations and trial initiatives with Radboud University Medical Center and participation in industry events (PEGS Summit Europe, Antibody Engineering & Therapeutics) create multiple entry points for co-development discussions, sponsored research, and technology licensing.

Technology Advantage Click-to-Release platform across ADCs and targeted radiotherapies highlights a differentiating value proposition for partners seeking controllable payload release, potential to accelerate development timelines, and opportunities to expand into combination therapies.

Commercial Readiness Mid-stage revenue and moderate funding position (revenue $10–25M, funding $65M) coupled with a compact team implies a lean, agile partner-seeking model; target mid-sized oncology-focused biotech and pharma companies looking to augment their pipeline with novel payload delivery technologies.